Emerging therapeutic targets in non-small cell lung cancer.
Over the last decade, systemic cancer therapies have evolved to exploit the growing knowledge of molecular aberrations involved in the development and progression of lung cancer. This review highlights the biological targets relevant in the treatment of non-small cell lung cancer.
Dy
Grace K
GK
Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY 14263, USA.
Adjei
Alex A
AA
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D019496:Cancer Vaccines / Q000627:therapeutic use; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000201:enzymology; D066246:ErbB Receptors / Q000037:antagonists & inhibitors; D006801:Humans; D018970:Insulin-Like Growth Factor Binding Protein 1 / Q000037:antagonists & inhibitors; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000201:enzymology; D051058:Oncogene Protein v-akt / Q000037:antagonists & inhibitors; D000081082:Phosphoinositide-3 Kinase Inhibitors; D011494:Protein Kinases; D020794:Receptor Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D058570:TOR Serine-Threonine Kinases; D019061:src-Family Kinases / Q000037:antagonists & inhibitors
D020533:Angiogenesis Inhibitors; D019496:Cancer Vaccines; D018970:Insulin-Like Growth Factor Binding Protein 1; D000081082:Phosphoinositide-3 Kinase Inhibitors; D011494:Protein Kinases; C546842:MTOR protein, human; D066246:ErbB Receptors; C080835:RON protein; D020794:Receptor Protein-Tyrosine Kinases; D019061:src-Family Kinases; D051058:Oncogene Protein v-akt; D058570:TOR Serine-Threonine Kinases